Irinotecan Hydrochloride
FDA-approved product (injectable, injection), marketed as Camptosar, Irinotecan Hydrochloride, Onivyde.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Adenocarcinoma
- Cancer
- Carcinoma
- Malignant Pancreatic Neoplasm
- Neoplasm
- Pancreatic carcinoma
- Pancreatic neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Topoisomerase 1 (top1) inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Irinotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease49.4% AI-predicted activityagainst E. coli50+ registered studies
- Ibrexafungerp CitrateExisting use: Vulvovaginal candidiasis49.4% AI-predicted activityagainst E. coliNo documented evidence found
- Mobocertinib SuccinateExisting use: Neoplasm, Non-small cell lung carcinoma49.2% AI-predicted activityagainst E. coliNo documented evidence found
- SparsentanExisting use: IGA glomerulonephritis49.2% AI-predicted activityagainst E. coli11 registered studies
- Epinastine HydrochlorideExisting use: Allergic conjunctivitis, Allergic disease, Eye allergy49.0% AI-predicted activityagainst E. coli10 registered studies
- Omidenepag IsopropylExisting use: Ocular hypertension, Open-angle glaucoma49.0% AI-predicted activityagainst E. coli1 registered study
- LesinuradExisting use: Gout, Hyperuricemia49.0% AI-predicted activityagainst E. coli22 registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more48.9% AI-predicted activityagainst E. coli50+ registered studies
- Prucalopride SuccinateExisting use: Constipation, Constipation disorder48.9% AI-predicted activityagainst E. coli7 registered studies
- FamciclovirExisting use: Eye infection, Genital herpes, Herpes Labialis and 3 more48.8% AI-predicted activityagainst E. coli25 registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more48.7% AI-predicted activityagainst E. coli50+ registered studies
- Nintedanib EsylateExisting use: Idiopathic pulmonary fibrosis, Interstitial pneumonitis, Non-small cell lung carcinoma and 1 more48.5% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
NCT00033657 · start 2002-08-15
Registered record
- Registry ID
- NCT00033657
- Conditions
- Esophageal Cancer; Gastric Cancer
- Interventions
- cisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-08-15
- Completion
- 2009-10
- Enrolment
- 97
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEsophageal Cancer; Gastric CancerInterventioncisplatin; irinotecan hydrochloride; paclitaxel; conventional surgery +1 morePhasePhase 2Registry statusCompletedImatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00248482 · start 2002-02
Registered record
- Registry ID
- NCT00248482
- Conditions
- Lung Cancer
- Interventions
- Cisplatin; Gleevec™; irinotecan
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-02
- Completion
- 2008-01
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLung CancerInterventionCisplatin; Gleevec™; irinotecanPhasePhase 2Registry statusCompletedZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer
NCT00030524 · start 2002-01
Registered record
- Registry ID
- NCT00030524
- Conditions
- Colorectal Cancer
- Interventions
- gefitinib
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-01
- Completion
- 2003-09
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventiongefitinibPhasePhase 2Registry statusCompletedZD 1839 Plus Combination Chemotherapy in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Colorectal Cancer
NCT00026364 · start 2001-11
Registered record
- Registry ID
- NCT00026364
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2001-11
- Completion
- Not recorded
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventionfluorouracil; gefitinib; irinotecan hydrochloride; leucovorin calciumPhasePhase 1Registry statusCompletedCetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer
NCT00020917 · start 2001-02
Registered record
- Registry ID
- NCT00020917
- Conditions
- Colorectal Cancer
- Interventions
- cetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calcium
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2001-02
- Completion
- 2004-02
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionColorectal CancerInterventioncetuximab; fluorouracil; irinotecan hydrochloride; leucovorin calciumPhasePhase 2Registry statusCompleted